| Not Yet Recruiting | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Y NCT07440290 | Cancer Research UK | Phase 2 / Phase 3 |
| Recruiting | DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 NCT05770544 | Cancer Research UK | Phase 2 / Phase 3 |
| Recruiting | A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma NCT07075185 | Kelonia Therapeutics, Inc. | Phase 1 |
| Recruiting | DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations NCT06988475 | Cancer Research UK | Phase 2 / Phase 3 |
| Recruiting | A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study NCT06271252 | OriCell Therapeutics Co., Ltd. | Phase 1 |
| Recruiting | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT06001788 | Kura Oncology, Inc. | Phase 1 |
| Recruiting | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Pos NCT05770037 | Cancer Research UK | Phase 2 / Phase 3 |
| Recruiting | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Canc NCT05770102 | Cancer Research UK | Phase 2 / Phase 3 |
| Active Not Recruiting | Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) NCT05797246 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture NCT05440240 | Regionshospitalet Silkeborg | Phase 4 |
| Unknown | Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors NCT06175780 | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | Phase 1 |
| Recruiting | Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patient NCT05252078 | Jiangxi Provincial Cancer Hospital | Phase 2 |
| Unknown | Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL NCT05186558 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Unknown | A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received O NCT05298683 | Hellenic Society of Hematology | Phase 2 |
| Unknown | A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by I NCT05147493 | Hellenic Society of Hematology | Phase 2 |
| Terminated | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations NCT05241873 | Blueprint Medicines Corporation | Phase 1 |
| Terminated | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC NCT05153408 | Blueprint Medicines Corporation | Phase 1 |
| Terminated | A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) NCT05160168 | Theseus Pharmaceuticals | Phase 1 / Phase 2 |
| Unknown | Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) M NCT05155215 | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors a NCT04572451 | Yana Najjar | Phase 1 |
| Active Not Recruiting | Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cance NCT04807166 | Wenjun Cheng | Phase 2 |
| Terminated | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC NCT04862780 | Blueprint Medicines Corporation | Phase 1 |
| Recruiting | Spanish Series of Patients Treated With the Radionuclide Lutetium177 NCT04949282 | Sociedad Española de Medicina Nuclear e Imagen Molecular | — |
| Unknown | External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patien NCT04697446 | Blueprint Medicines Corporation | — |
| Unknown | Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian NCT04556071 | Xiaoxiang Chen | Phase 2 |
| Unknown | Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer NCT04566952 | Xiaoxiang Chen | Phase 2 |
| Terminated | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer NCT04222972 | Hoffmann-La Roche | Phase 3 |
| Completed | Evaluation of in Vitro Devices on Self-collected Vaginal Swab and Urine Sample for Testing of Human Papilloma NCT04312737 | Hiantis Srl | — |
| Unknown | Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma NCT04309084 | Celularity Incorporated | Phase 1 |
| Terminated | Natural Killer Cell (CYNK-001) Infusions in Adults with AML NCT04310592 | Celularity Incorporated | Phase 1 |
| Terminated | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRP NCT04249947 | Poseida Therapeutics, Inc. | Phase 1 |
| Recruiting | HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors NCT03911388 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma NCT04124198 | Christian von Buchwald | N/A |
| Completed | A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymp NCT03744676 | Juno Therapeutics, a Subsidiary of Celgene | Phase 2 |
| Suspended | Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malig NCT03722186 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Terminated | A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomi NCT03495921 | Gradalis, Inc. | Phase 3 |
| Completed | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Can NCT03037385 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Completed | Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors NCT02909452 | Syndax Pharmaceuticals | Phase 1 |
| Active Not Recruiting | Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL NCT02690545 | UNC Lineberger Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Completed | Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors NCT02897778 | Syndax Pharmaceuticals | Phase 1 |
| Active Not Recruiting | Administration of T Lymphocytes for Prevention of Relapse of Lymphomas NCT02663297 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Terminated | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer NCT02543645 | Celldex Therapeutics | Phase 1 |
| Terminated | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma NCT02386111 | Celldex Therapeutics | Phase 1 |
| Completed | A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative NCT02158858 | Constellation Pharmaceuticals | Phase 1 / Phase 2 |
| Unknown | Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous In NCT01995942 | Royal Marsden NHS Foundation Trust | — |
| Unknown | Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate He NCT01556815 | Shandong Cancer Hospital and Institute | Phase 2 |
| Unknown | Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic NCT01579253 | Ludwig-Maximilians - University of Munich | — |
| Terminated | Intended Use Study of the BD SurePath Plus™ Pap NCT01234480 | Becton, Dickinson and Company | — |
| Terminated | Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) NCT01009593 | Abbott | Phase 3 |
| Unknown | Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks NCT01037049 | Royal Marsden NHS Foundation Trust | Phase 2 |
| Completed | A Trial In Patients With Advanced Cancer And Leukemia NCT00878189 | Pfizer | Phase 1 |
| Unknown | Low Rectal Cancer Study (MERCURY II) NCT02005965 | Royal Marsden NHS Foundation Trust | — |
| Completed | A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma NCT00102609 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 |
| Approved For Marketing | Vorasidenib Expanded Access Program NCT05592743 | Servier | — |